title: Clinical study on fluvoxamine combined with oxycodone prolonged-release tablets in treating patients with moderate to severe cancer pain.
abstract: OBJECTIVE
  To observe treatment effects and safety of fluvoxamine combined with oxycodone prolonged-release tablets in treating patients with moderate to severe cancer pain.
  
  
  METHODS
  Patients confirmed pathologically with cancer and complicated with moderate to severe pain, were divided into control and experimental groups. Oxycodone prolonged-release tablets, with or without fluvoxamine, were administrated to all study patients until pain relief. Degree of pain relief, dose of oxycodone prolonged-release tablets, side effects and quality of life were compared before and after treatment.
  
  
  RESULTS
  In total, 120 patients were recruited. No statistically significant difference was detected regarding age, gender, types of cancer, KPS between two groups of patients (P> 0.05). Baseline pain score of patients with moderate pain in treatment and control group was 4.9±0.8 and 5.1±0.8, respectively; and decreased to 1.8±1.1 and 1.2±1.1 after treatment, respectively. Pain intensity was significantly reduced in the treatment group (P =0.028). Average daily consumption of oxycodone prolonged- release tablets was (54.0±19.6) mg and (44.7± 18.7) mg respectively, which is lower in treatment grpup than in control group, but the difference was not statistically significant (P=0.065). Baseline pain score of patients with severe pain in treatment and control groups were 8.3±1.1 and 8.3±1.1, respectively; and pain intensity after treatment decreased to 2.9±1.0 and 2.3±1.0. Pain intensity was significantly reduced in the treatment group, with statistical significance (P =0.026). Average daily consumption of oxycodone prolonged-release tablets was (132.0±42.2) mg and (110.7±33.9) mg, respectively, which is lower in treatment group than in control group, and the difference was statistically significant (P=0.035). In terms of quality of life, patients in treatment group had better performance status, daily activity, mood, and sleep than that in control group (P < 0.05). Patients in two groups had similar side effects, eg., constipation, nausea/vomiting, lethargy, dizziness, itchy skin, dysuria, and ataxia. Lower incidence of nausea/vomiting, lethargy, was obtained from patients in treatment than in control group, while significant low constipation was observed in treatment than in control group (35.0% vs 49.2%, P=0.026).
  
  
  CONCLUSIONS
  Fluvoxamine combined with oxycodone prolonged-release tablets could be more effective in treating patients with cancer pain, and could reduce the dosage of oxycodone prolonged-release tablets and thus be associated with lower side effects, and improved quality of life.
authors.affiliation: Department of Medical Oncology, The People's Hospital of Taixing City, Taixing, China E-mail : huangxinen06@aliyun.com.
authors.forename: Yang
authors.initials: Y
authors.lastname: Xiao
authors.forename: Jun
authors.initials: J
authors.lastname: Liu
authors.forename: Xin-En
authors.initials: XE
authors.lastname: Huang
authors.forename: Li-Hua
authors.initials: LH
authors.lastname: Ca
authors.forename: Yi-Min
authors.initials: YM
authors.lastname: Ma
authors.forename: Wei
authors.initials: W
authors.lastname: Wei
authors.forename: Rong-Xia
authors.initials: RX
authors.lastname: Zhang
authors.forename: Xiao-Hong
authors.initials: XH
authors.lastname: Huang
authors.forename: Juan
authors.initials: J
authors.lastname: Chang
authors.forename: Yi-Jia
authors.initials: YJ
authors.lastname: Wu
mesh_terms: D000701:Analgesics, Opioid / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004359:Drug Therapy, Combination; D005260:Female; D016666:Fluvoxamine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000150:complications*; D010098:Oxycodone / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D010147:Pain Measurement; D011788:Quality of Life; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000701:Analgesics, Opioid; D003692:Delayed-Action Preparations; D016666:Fluvoxamine; D010098:Oxycodone; D017367:Selective Serotonin Reuptake Inhibitors